<DOC>
	<DOCNO>NCT00630175</DOCNO>
	<brief_summary>The primary objective evaluate hypnotic efficacy zolpidem-MR ( modified release ) 12.5 mg zolpidem 10 mg market product comparison placebo patient primary insomnia sleep maintenance difficulty , use polysomnography ( PSG ) record patient sleep questionnaire . The secondary objective evaluate clinical safety tolerability zolpidem-MR 12.5 mg zolpidem 10 mg market product comparison placebo .</brief_summary>
	<brief_title>Evaluation Hypnotic Properties Zolpidem-MR 12.5 mg Zolpidem 10 mg Marketed Product Compared Placebo Patients With Primary Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Zolpidem</mesh_term>
	<mesh_term>Hypnotics Sedatives</mesh_term>
	<criteria>Diagnosis primary insomnia base Diagnostic Statistical Manual Mental Disorders ( DSMIV ) criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Insomnia</keyword>
</DOC>